Vaccine Breakthrough? Gilead Says Coronavirus Drug Is Working Description video: Apr.17 — Gilead Sciences Inc. shares climbed after a report that a group of coronavirus patients being treated in Chicago were seeing rapid recoveries in fever and respiratory symptoms. Bloomberg’s […]
Vaccine Breakthrough? Gilead Says Coronavirus Drug Is Working
Apr.17 — Gilead Sciences Inc. shares climbed after a report that a group of coronavirus patients being treated in Chicago were seeing rapid recoveries in fever and respiratory symptoms. Bloomberg’s Annmarie Hordern reports on “Bloomberg Daybreak: Europe.”
Gilead Sciences Unveils Experimental Coronavirus Vaccine
Gilead Sciences shares jump 13% on Monday amid reports of human testing for an experimental coronavirus vaccine.
A drug called remdesivir is an antiviral drug developed to fight infectious diseases, including Ebola and SARS.. It will be tested by a medical team from the China-Japan Friendship Hospital located in Beijing to verify its effectiveness in treating coronavirus.
Tests of the drug will take place in Wuhan, where the outbreak of the epidemic began. The study will involve 270 patients with mild to moderate pneumonia caused by coronavirus.
Coronavirus claimed more lives 360 and infected over 17 thousand people all over the world, bringing down global markets that are highly responsive on the continued spread of the disease. However, the value of a number of pharmaceutical companies has increased in value after the announcement of work on various types of vaccines for this disease.
It’s worth noting that the experimental drug Gilead has not been approved for use by any pharmaceutical regulator in the world.. However, it will be used to treat coronavirus patients due to the lack of other options..
The drug has already been used on the first infected US resident. Subsequent observations showed that he began to recover. This case contributed to further testing of the drug with positive expectations..
Litigation in China could speed up local drug regulator’s approval of remdesivir, Bloomberg reports. According to the rules of this country, drugs can be approved on a conditional basis with clinical data demonstrating efficacy against life-threatening diseases without existing therapies..